XML 43 R33.htm IDEA: XBRL DOCUMENT

Shareholders’ Equity (Tables)

3 Months Ended

Mar. 31, 2025

Schedule of Stock-based Compensation Expense

The Company recognized stock-based compensation expense as follows (in thousands):


	Three Months Ended March 31,
		2025		2024
Subscriber related		$	69	$	79
Sales and marketing		(3,201)		4,707
Technology and development		3,280		3,878
General and administrative		3,316		4,313
Total stock-based compensation expense		$	3,464	$	12,977

Schedule of of Stock Option Activity

A summary of time-based stock option activity for the three months ended March 31, 2025 is as follows (in thousands, except share and per share amounts):


	Number of Shares	Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (Years)
Outstanding as of December 31, 2024	10,196,232	$	6.13	$	1,036	4.4

Exercised	(2,150,631)	$	1.31
Forfeited or expired	(300)	$	9.98
Outstanding as of March 31, 2025	8,045,301	$	7.42	$	1,947	4.3

Options vested and exercisable as of March 31, 2025	7,726,219	$	7.66	$	1,660	4.6

A summary of activity under the Plan for market and service-based stock options for the three months ended March 31, 2025 is as follows (in thousands, except share and per share amounts):


	Number of Shares	Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (Years)
Outstanding as of December 31, 2024	4,453,297	$	12.75	$	—	2.7

Outstanding as of March 31, 2025	4,453,297	$	12.75	$	—	2.4

Options vested and exercisable as of March 31, 2025	3,994,964	$	11.96	$	—	2.3

Schedule of Nonvested Restricted Stock Units Activity

A summary of the Company’s time-based restricted stock unit activity during the three months ended March 31, 2025 is as follows:


	Number of Shares	Weighted Average Grant-Date Fair Value
Unvested at December 31, 2024	26,709,357	$	2.47
Granted	2,935,804	$	1.26
Vested	(244,312)	$	7.50
Forfeited or expired	(104,736)	$	2.76
Unvested at March 31, 2025	29,296,113	$	2.31

A summary of the Company’s performance-based restricted stock unit activity during the three months ended March 31, 2025 is as follows:


	Number of Shares	Weighted Average Grant-Date Fair Value
Unvested at December 31, 2024	3,031,828	$	5.61
Granted	1,263,273	$	3.01


Unvested at March 31, 2025	4,295,101	$	4.85

Schedule of Outstanding Warrants

A summary of the Company’s outstanding warrants as of March 31, 2025, are presented below (in thousands, except number of shares and exercise price):


	Number of Shares	Weighted Average Exercise Price		Total Intrinsic Value		Weighted Average Remaining Contractual Life (Years)
Outstanding as of December 31, 2024	166,670	$	17.40	$	—	7.6


Forfeited or expired	(3)	$	133,500.00
Outstanding as of March 31, 2025	166,667	$	15.00	$	—	7.3